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surgery occurred a mean of 4.2±2.5 years ago. Based on the HADS, 31% and 16% 
of patients had clinically meaningful anxiety and depression, respectively. 
Depression was significantly associated with poorer totaI IBDQ scores (p<0.0001) 
and higher BIQ scores (p<0.0001). Females are 2.15 times more likely to have 
anxiety than males (OR 2.15, 95% CI 1.19-3.88). Other factors associated with 
anxiety include loss of work productivity (OR 1.39, 95% CI 1.18-1.64) and poorer 
body image (OR 1.12, 95% CI 1.04-1.20). CONCLUSIONS: The findings from this 
multi-national study provide insight on important factors to inform patient-
physician communications both prior to and post-colectomy.  
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OBJECTIVES: Fatigue is the most common side-effect of treatment for chronic 
hepatitis C virus (CHC) infection with peginterferon-α and ribavirin (PR). 
Adequacy of the Fatigue Severity Scale (FSS) total scores for evaluating fatigue 
from the patients’ perspective in CHC trials was assessed using blinded data 
from two CHC clinical trials. METHODS: 386 treatment-naïve patients (PILLAR) 
and 462 treatment-experienced patients (ASPIRE) were randomized to receive 
simeprevir (TMC435), a potent, oral, once-daily, investigational HCV NS3/4A 
protease inhibitor in Phase III clinical development and PR or placebo/PR. 
Patients completed the FSS and EQ5D in their native language throughout the 72 
week trials. Reliability of the FSS was evaluated using Cronbach’s co-efficient a 
at Week 24 (internal consistency reliability) and intraclass correlation (ICC) 
between FSS at Weeks 12 and 24 in stable patients (<0.5 g/dL change in 
hemoglobin between Weeks 12/24). Concurrent validity was assessed as 
correlation with the EQ5D visual analog scale (VAS). Known-groups validity of 
FSS scores was assessed using mean comparison by levels on the EQ5D daily 
activity item and by clinician-rated fatigue AEs at Week 24. Distribution- and 
anchor-based methods identified values representing a meaningful change in 
individual and mean FSS scores. RESULTS: FSS scores were highly reliable 
(Cronbach’s α = 0.95, 0.96 and ICC: 0.74, 0.86 for PILLAR and ASPIRE, respectively). 
Concurrent validity (correlation of FSS and EQ5D VAS=-0.63, -0.66) and known 
groups validity (mean FSS scores by EQ5D daily activity levels or fatigue AEs 
severity (p < 0.05) were confirmed. Analyses suggest that a meaningful change in 
mean FSS scores ranges from 0.33-0.82, and that a 1 point change is a 
conservative indicator of an important within-subject change in FSS score. 
CONCLUSIONS: The Fatigue Severity Scale provides reliable and valid 
assessment and quantification of fatigue for clinical trials in patients with CHC 
infection.  
 
PGI25  
DEVELOPMENT OF PATIENT-REPORTED OUTCOMES (PRO) AND OBSERVER-
REPORTED OUTCOMES (OBSRO) MEASURES FOR PEDIATRIC ULCERATIVE 
COLITIS: CONCEPT ELICITATION FINDINGS  
Yen L1, Flood E2, Beusterien K3, Tucker J2, Stout B2, Ahmadi A2, Silberg DG1, Erder M1 
1Shire Pharmaceuticals, Wayne, PA, USA, 2Oxford Outcomes, Inc., an ICON plc company, 
Bethesda, MD, USA, 3Oxford Outcomes Inc., Bethesda, MD, USA  
OBJECTIVES: The purpose of this research was to develop an electronic daily sign 
and symptom diary, the Daily Ulcerative Colitis Scale (DUCS), including a patient 
reported outcomes (PRO) version for children 8-17 years and an observer 
reported outcomes (ObsRO) version for caregivers of children aged 5-10 years. 
METHODS: Open-ended one-on-one concept elicitation interviews were 
conducted with children aged 8-17 years with a documented history of mild to 
moderate ulcerative colitis confirmed by endoscopy, recruited from three clinical 
centers. The interviews focused on signs or symptoms associated with UC. In 
addition, five pediatric gastroenterologists and three nurses were interviewed 
about the pediatric UC signs/symptoms, and parent blogs on an active UC 
website were reviewed; the blogs included discussions on 26 children with UC. 
Interview transcripts were developed, and a thematic analysis was conducted in 
which each new concept identified was coded using MaxQDA. RESULTS: The 
concept elicitation interviews included 22 children in remission (six aged 8-12; 16 
aged 13-17) and 10 children with active disease (four aged 8-12; six aged 13-17). 
Information saturation (i.e., no new information reported in last patient 
interview) was achieved. A core set of seven signs/symptoms in pediatric UC 
emerged: abdominal pain, blood in stool, frequent stools, diarrhea, stool urgency, 
nocturnal stools, and tiredness. No substantial differences were observed across 
different ages, and descriptions were largely consistent across patients. Even 
when in remission, children reported occasional symptoms. The HCP interviews 
and blog data substantiated the interview findings; the HCPs confirmed that 
signs/symptoms of UC do not vary by age. CONCLUSIONS: Children with UC 
were able to report their signs/symptoms associated with UC, and these data 
informed the development of two measures with phrasing that should resonate 
with the pediatric and caregiver populations. These will be tested in cognitive 
debriefing interviews.  
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OBJECTIVES: To analysis of the pattern of the consumption of histamine H2-
receptor antagonists (H2RAs) and proton pump inhibitors (PPIs) (ATC subgroup 
A02B) in Serbia in correlation with Scandinavian countries (Denmark, Norway, 
Sweden and Finland). METHODS: The data on consumption of medicines during 
the four-year period (2007-2010) have been provided from the databases of the 
national regulatory agencies. The results were expressed as the number of 
defined daily doses per 1000 inhabitants per day (DID). A qualitative analysis was 
carried out according to the drug utilization 90% (DU90%) approach. RESULTS: 
During the period 2007-2010, the overall consumption of A02B subgroup 
medicines in Serbia decreased by 7.8%, opposite to Scandinavian countries 
where the consumption continuously increased in all countries, up to 56% in 
Denmark. In 2010, H2RAs accounted for 71.78% (16.46DID) of medicines used 
within A02B subgroup in Serbia, while in Scandinavian countries the share of 
H2RAs was in the range of 1.08 DID in Sweden up to 5.75 DID in Norway. Despite 
the increase by 34.3%, consumption of PPIs in 2010 in Serbia (6.45 DID) was up to 
7.6 times lower than in the Scandinavian countries (49.1 DID in Denmark). The 
bulk of prescription (DU90%) in 2010 was made up of 3 (out of 7) medicines in 
Serbia, 2, 4 and 5 (out of 14) medicines in Sweden, Denmark and Finland 
respectively, and 5 (out of 10) medicines in Norway. Most frequently used 
medicine in Serbia was ranitidine (55.9%), in Sweden and Denmark omeprazole 
(80.3% and 30.3% respectively), in Norway esomeprazole (34.1%) and in Finland 
pantoprazole (28.5%). CONCLUSIONS: The overall utilization of medicines from 
A02B subgroup was notably lower in Serbia than in Scandinavian countries. 
Besides the quantity, the pattern of use showed significant differences 
suggesting that implementation of guidelines in Serbia is needed in order to 
achieve harmonization in prescribing practice.  
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OBJECTIVES: Few studies have explored how utilization of outpatient services 
differ for HIV/HCV coinfected patients compared to HIV or HCV monoinfected 
patients. The objectives of this study were to compare annual outpatient clinic 
visit rates between coinfected and monoinfected patients and to compare 
utilization of HIV and HCV therapies between coinfected and monoinfected 
patients. METHODS: Data were retrieved from the 2005-2010 National Hospital 
Ambulatory Medical Care Surveys. Clinic visits with a primary or secondary ICD-
9-CM diagnosis code for HIV or HCV were included. Coinfection included visits 
with both HIV and HCV codes. Monoinfection included visits with only HIV or 
HCV codes. Patients <15 years of age at time of visit were excluded. Demographic 
characteristics and select comorbidities were compared by infection status using 
chi-square and ANOVA tests. Visit rates were computed using survey weights. 
RESULTS: Approximately 11,352,000 visits met study criteria for patients with 
HIV/HCV (8%), HIV (70%), or HCV (22%). The HCV cohort was older and had the 
highest proportion of females and whites as compared to HIV/HCV and HIV 
cohorts. The following comorbidities varied significantly across the three cohorts 
(HIV/HCV, HIV, HCV): current tobacco use (40%, 27%, 30%), depression (32%, 23%, 
24%), diabetes (9%, 10%, 17%), and chronic renal failure (<1%, 3%, 5%), (p<0.001 for 
all variables). HIV/HCV visit rates were lower than both HIV and HCV visits rates 
and varied little across all study years. In contrast, there was a decrease in 
annual HIV visit rates and an increase in annual HCV visit rates. HIV therapy 
utilization increased for both HIV/HCV and HIV cohorts; the increase was more 
pronounced in the HIV/HCV cohort. HCV therapy utilization remained low for 
both HIV/HCV and HCV cohorts for all years. CONCLUSIONS: Low utilization of 
HCV therapy for HIV/HCV patients and HCV patients warrants further 
investigation.  
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OBJECTIVES: A previous study indicated that after one year, the proportion of 
patients with a dose augmentation was higher with infliximab than with 
adalimumab. The objective of this study was to analyze, in a real world setting, 
trends in dose changes over a three-year period. METHODS: A retrospective 
cohort study was conducted using data from the Regie de l'assurance maladie du 
Quebec (RAMQ) for a randomly selected group of patients with a CD diagnosis, 
who had initiated (6month washout period) adalimumab or infliximab between 
February 2008 and March 2011. For adalimumab, dose increase was considered 
when the dose received exceeded 40mg every other week over at least an 8-week 
period. For infliximab, dose increase was considered either when the dose was 
increased or interval between doses was reduced for two periods of 8 weeks after 
the third injection. Statistical analyses were conducted using chi square test. 
RESULTS: The cohort included 1,517 patients (mean age: 33.9 years, 55.4% 
females). During the study period, 1,004 patients initiated infliximab (28 
previously used adalimumab) and 513 patients initiated adalimumab (195 
previously used infliximab). After 36 months, 28.2%(275/976) of patients with 
infliximab and 23.0%(73/318) of patients with adalimumab experienced a dose 
increase (p<0.05). For the non-naive patient subgroups, dose escalation occurred 
for 42.9%(12/28) with infliximab and for 27.2%(53/195) with adalimumab (p<0.05). 
Average annual cost of adalimumab was CDN$26,957 and CDN$18,577 for 
